Galapagos NV
GLPG33.350USD
+0.640+1.96%
Horário de mercado （ET）Cotações atrasadas em 15 min
2.20BValor de mercado
PerdaP/L TTM
Mais detalhes de Galapagos NV Empresa
Galapagos NV is a Belgium-based clinical-stage biotechnology company. The Company is engaged in the discovery and development of small molecule medicines with modes of action. Its pipeline comprises Phase 3, 2, 1, pre-clinical studies and discovery small-molecule and antibody programs in cystic fibrosis, inflammation, and other indications. The Company focuses on developing a portfolio of clinical-stage therapies for the enhancement of existing treatment paradigms. It develops transformational medicines in areas of high unmet need by combining internal with external science with the goal to add years of life and improve of life of patients across the globe. It discovers which proteins that are involved in causing diseases such as, rheumatoid, arthritis, inflammatory bowel disease and fibrosis. The Company acquired CellPoint and AboundBio in order to develop a cell therapy, which is a potential transformative treatment of different types of cancer.
Informações da empresa
Código da empresaGLPG
Nome da EmpresaGalapagos NV
Data de listagemMay 06, 2005
CEOHenry Gosebruch
Número de funcionários704
Tipo de títulosOrdinary Share
Fim do ano fiscalMay 06
EndereçoGeneraal De Wittelaan L11 A3
CidadeMALINES (MECHELEN)
Bolsa de valoresEuronext Amsterdam
PaísBelgium
Código postal2800
Telefone3215342900
Sitehttps://www.glpg.com/
Código da empresaGLPG
Data de listagemMay 06, 2005
CEOHenry Gosebruch
Executivos da empresa
Nome
Nome/Posição
Posição
Ações detidas
Variação
Mr. Andrew (Andy) Dickinson
Mr. Andrew (Andy) Dickinson
Non-Executive Non-Independent Director
Non-Executive Non-Independent Director
--
--
Mr. Simon Sturge
Mr. Simon Sturge
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Dr. Susanne Schaffert, Ph.D.
Dr. Susanne Schaffert, Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Dr. Linda Higgins, Ph.D.
Dr. Linda Higgins, Ph.D.
Non-Executive Non-Independent Director
Non-Executive Non-Independent Director
--
--
Mr. Oleg Nodelman
Mr. Oleg Nodelman
Non-Executive Non-Independent Director
Non-Executive Non-Independent Director
--
--
Ms. Annelies Missotten
Ms. Annelies Missotten
Chief Human Resources Officer, Executive Vice President, Member of the Management Board
Chief Human Resources Officer, Executive Vice President, Member of the Management Board
--
--
Mr. Peter Guenter
Mr. Peter Guenter
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. Jerome Contamine
Mr. Jerome Contamine
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
--
--
Ms. Elisabeth Svanberg
Ms. Elisabeth Svanberg
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Ms. Valeria Cnossen
Ms. Valeria Cnossen
Executive Vice President, General Counsel, Member of the Management Board
Executive Vice President, General Counsel, Member of the Management Board
--
--
Ver Mais
Nome
Nome/Posição
Posição
Ações detidas
Variação
Mr. Andrew (Andy) Dickinson
Mr. Andrew (Andy) Dickinson
Non-Executive Non-Independent Director
Non-Executive Non-Independent Director
--
--
Mr. Simon Sturge
Mr. Simon Sturge
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Dr. Susanne Schaffert, Ph.D.
Dr. Susanne Schaffert, Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Dr. Linda Higgins, Ph.D.
Dr. Linda Higgins, Ph.D.
Non-Executive Non-Independent Director
Non-Executive Non-Independent Director
--
--
Mr. Oleg Nodelman
Mr. Oleg Nodelman
Non-Executive Non-Independent Director
Non-Executive Non-Independent Director
--
--
Ms. Annelies Missotten
Ms. Annelies Missotten
Chief Human Resources Officer, Executive Vice President, Member of the Management Board
Chief Human Resources Officer, Executive Vice President, Member of the Management Board
--
--
Detalhamento da receita
Moeda: EURAtualizado em: dom, 6 de jul
Moeda: EURAtualizado em: dom, 6 de jul
FY2024
FY2023
FY2022
FY2021
FY2020
FY2019
Sem dados
Por RegiãoEUR
Nome
Receita
Proporção
United States
240.79M
87.35%
Europe
34.86M
12.65%
Por Empresa
Por Região
Sem dados
Distribuição de ações
Atualizado em: sex, 6 de jun
Atualizado em: sex, 6 de jun
Investidores
Tipos de investidores
Investidores
Investidores
Proporção
Tang Capital Management, LLC
6.01%
Fidelity Management & Research Company LLC
2.25%
BVF Partners L.P.
2.21%
Prosight Capital
2.00%
Deep Track Capital LP
1.12%
Other
86.41%
Investidores
Investidores
Proporção
Tang Capital Management, LLC
6.01%
Fidelity Management & Research Company LLC
2.25%
BVF Partners L.P.
2.21%
Prosight Capital
2.00%
Deep Track Capital LP
1.12%
Other
86.41%
Tipos de investidores
Investidores
Proporção
Hedge Fund
15.79%
Investment Advisor
3.83%
Investment Advisor/Hedge Fund
2.06%
Research Firm
0.38%
Sovereign Wealth Fund
0.18%
Bank and Trust
0.03%
Other
77.73%
Participação acionária institucional
Atualizado em: ter, 1 de jul
Atualizado em: ter, 1 de jul
Período do relatório
N.º de instituições
Ações detidas
Proporção
Variação
2025Q2
173
14.68M
22.27%
-2.24M
2025Q1
179
31.47M
47.75%
+14.44M
2024Q4
185
31.50M
47.80%
+9.00M
2024Q3
191
14.15M
21.47%
-8.51M
2024Q2
205
20.48M
31.08%
-2.95M
2024Q1
212
21.04M
31.93%
-2.58M
2023Q4
223
20.26M
30.74%
-3.01M
2023Q3
221
19.52M
29.63%
-4.10M
2023Q2
254
20.05M
30.43%
-5.06M
2023Q1
285
18.55M
28.15%
-1.32M
Ver Mais
Atividade dos acionistas
Nome
Ações detidas
Proporção
Variação
Var. %
Data
Tang Capital Management, LLC
3.96M
6.01%
+1.42M
+55.71%
Mar 31, 2025
Fidelity Management & Research Company LLC
1.48M
2.25%
-35.02K
-2.31%
Mar 31, 2025
BVF Partners L.P.
1.45M
2.21%
-115.00K
-7.33%
Mar 31, 2025
Prosight Capital
1.31M
2%
+289.90K
+28.28%
Mar 31, 2025
Deep Track Capital LP
741.07K
1.12%
-39.71K
-5.09%
Mar 31, 2025
Finepoint Capital LP
656.59K
1%
-18.18K
-2.69%
Mar 31, 2025
Segall Bryant & Hamill, LLC
651.46K
0.99%
-34.41K
-5.02%
Mar 31, 2025
Hudson Bay Capital Management LP
565.00K
0.86%
+10.70K
+1.93%
Mar 31, 2025
Greenlight Capital, Inc.
482.75K
0.73%
+3.38K
+0.71%
Mar 31, 2025
Renaissance Technologies LLC
330.80K
0.5%
+34.70K
+11.72%
Mar 31, 2025
Ver Mais
ETFs Relacionados
Atualizado em: sáb, 2 de ago
Atualizado em: sáb, 2 de ago
Nome
Proporção
ALPS Medical Breakthroughs ETF
1.24%
Avantis International Small Cap Equity ETF
0.12%
iShares Biotechnology ETF
0.09%
ActivePassive International Equity ETF
0.07%
ProShares Ultra Nasdaq Biotechnology
0.05%
Invesco Nasdaq Biotechnology ETF
0.05%
Avantis Responsible International Equity ETF
0.02%
Avantis International Equity ETF
0.01%
iShares Health Innovation Active ETF
0%
ALPS Medical Breakthroughs ETF
Proporção1.24%
Avantis International Small Cap Equity ETF
Proporção0.12%
iShares Biotechnology ETF
Proporção0.09%
ActivePassive International Equity ETF
Proporção0.07%
ProShares Ultra Nasdaq Biotechnology
Proporção0.05%
Invesco Nasdaq Biotechnology ETF
Proporção0.05%
Avantis Responsible International Equity ETF
Proporção0.02%
Avantis International Equity ETF
Proporção0.01%
iShares Health Innovation Active ETF
Proporção0%
Dividendo
Um total de
0.00
USD foi distribuído em dividendos nos últimos 5 anos.
Data
Dividendo
Data de registro
Data de pagamento
Data ex-dividendo
Sem dados
Desdobramento de ações
Data
Tipo
Proporção
Sem dados
Data
Tipo
Proporção
Sem dados
